CN1057097C - 封阻补体激活的嵌合蛋白 - Google Patents

封阻补体激活的嵌合蛋白 Download PDF

Info

Publication number
CN1057097C
CN1057097C CN94194284A CN94194284A CN1057097C CN 1057097 C CN1057097 C CN 1057097C CN 94194284 A CN94194284 A CN 94194284A CN 94194284 A CN94194284 A CN 94194284A CN 1057097 C CN1057097 C CN 1057097C
Authority
CN
China
Prior art keywords
protein
chimeric protein
mcp
cell
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94194284A
Other languages
English (en)
Chinese (zh)
Other versions
CN1138863A (zh
Inventor
J·-L·高
P·J·希金斯
C·G·叶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THOUSAND YEARS MEDICAMENTS Inc
Original Assignee
CytoMed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CytoMed Inc filed Critical CytoMed Inc
Publication of CN1138863A publication Critical patent/CN1138863A/zh
Application granted granted Critical
Publication of CN1057097C publication Critical patent/CN1057097C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN94194284A 1993-09-24 1994-09-23 封阻补体激活的嵌合蛋白 Expired - Fee Related CN1057097C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12659693A 1993-09-24 1993-09-24
US126,596 1993-09-24
US310,416 1994-09-22
US08/310,416 US5679546A (en) 1993-09-24 1994-09-22 Chimeric proteins which block complement activation

Publications (2)

Publication Number Publication Date
CN1138863A CN1138863A (zh) 1996-12-25
CN1057097C true CN1057097C (zh) 2000-10-04

Family

ID=26824842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94194284A Expired - Fee Related CN1057097C (zh) 1993-09-24 1994-09-23 封阻补体激活的嵌合蛋白

Country Status (9)

Country Link
US (2) US5679546A (enExample)
EP (1) EP0723555B1 (enExample)
JP (2) JP3860605B2 (enExample)
CN (1) CN1057097C (enExample)
AT (1) ATE380875T1 (enExample)
AU (1) AU697167B2 (enExample)
CA (1) CA2172610A1 (enExample)
DE (1) DE69435049D1 (enExample)
WO (1) WO1995008570A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
US5866402A (en) * 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
FR2736916B1 (fr) * 1995-07-21 1997-09-19 Univ Paris Curie Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
DE69828615T2 (de) * 1997-10-31 2005-12-01 Walter Reed Army Institute Of Research Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
EP3056516A1 (en) * 1998-02-20 2016-08-17 Genentech, Inc. Inhibitors of complement activation
US7112327B2 (en) * 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
EP1228237A1 (en) * 1999-11-01 2002-08-07 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
ATE449791T1 (de) 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
EP1539811A4 (en) * 2002-09-16 2006-05-24 Elusys Therapeutics Inc PREPARATION OF BISPEQIFIC MOLECULES WITH POLYETHYLENE GLYCOL LINKER
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
WO2005069726A2 (en) 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US8703693B2 (en) * 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
CA2562957C (en) * 2004-03-31 2013-05-21 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
CN103505728A (zh) * 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
DK2500030T4 (en) * 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
JP5250548B2 (ja) * 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体ｈ因子の標的化
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
MX2009009200A (es) * 2007-03-01 2009-10-28 Advanced Vision Therapies Inc Tratamiento de enfermedades caracterizadas por la inflamacion.
WO2008140653A2 (en) * 2007-03-14 2008-11-20 Taligen Therapeutics, Inc. Humaneered anti-factor b antibody
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2009151634A1 (en) * 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
CN102958535A (zh) 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
CN102234332B (zh) * 2010-04-26 2014-12-17 浙江海正药业股份有限公司 一种重组人血白蛋白及其融合蛋白的分离纯化工艺
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
BR112012033119A2 (pt) 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
CA2840270C (en) 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US9243070B2 (en) 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
AU2015223056B2 (en) 2014-02-27 2020-10-01 Allergan, Inc. Complement Factor Bb antibodies
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
BR112017011170A2 (pt) 2014-12-18 2018-02-27 Hoffmann La Roche método para determinar a citotoxicidade dependente do complemento de uma composição
EP3359663A4 (en) 2015-09-24 2019-08-14 The Trustees of The University of Pennsylvania COMPOSITION AND METHOD FOR THE TREATMENT OF A COMPLEMENT-MEDIATED DISEASE
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
LT3394089T (lt) * 2015-12-23 2021-11-25 eleva GmbH Polipeptidai, skirti komplemento aktyvacijos inhibicijai
CA3029106A1 (en) * 2016-06-28 2018-01-04 Universitat Ulm Complement inhibitors and uses thereof
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
JP7444968B2 (ja) * 2019-04-13 2024-03-06 ナショナル・センター・フォー・セル・サイエンス Ｄａｆ－ｍｃｐキメラタンパク質、その製造方法及び補体系が関係する病的状態を処置するためのキメラタンパク質の使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US4774180A (en) * 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
US5264357A (en) * 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
EP0489116B1 (en) * 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3
CA2049964A1 (en) * 1990-01-26 1991-07-27 Biogen, Inc. C4 binding protein fusion proteins
EP0512733A2 (en) * 1991-05-03 1992-11-11 Washington University Modified complement system regulator
US5252216A (en) * 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins

Also Published As

Publication number Publication date
ATE380875T1 (de) 2007-12-15
AU697167B2 (en) 1998-10-01
US5679546A (en) 1997-10-21
JPH09502985A (ja) 1997-03-25
WO1995008570A1 (en) 1995-03-30
EP0723555B1 (en) 2007-12-12
JP2005041882A (ja) 2005-02-17
AU8071994A (en) 1995-04-10
US5851528A (en) 1998-12-22
CA2172610A1 (en) 1995-03-30
JP3860605B2 (ja) 2006-12-20
EP0723555A4 (en) 1999-04-28
DE69435049D1 (de) 2008-01-24
CN1138863A (zh) 1996-12-25
EP0723555A1 (en) 1996-07-31

Similar Documents

Publication Publication Date Title
CN1138863A (zh) 封阻补体激活的嵌合蛋白
CN1289526C (zh) 干细胞因子
WO1995008570A9 (en) Chimeric proteins which block complement activation
CN1341660A (zh) 一种新的多肽——人白细胞介素受体－配体(il－17b和il－17br)32.56和编码这种多肽的多核苷酸
CN1326985A (zh) 一种新的多肽——人嘌呤受体21.23和编码这种多肽的多核苷酸
CN1341626A (zh) 一种新的多肽——结合蛋白RanBP2－14.52和编码这种多肽的多核苷酸
CN1343687A (zh) 一种新的多肽——转运蛋白17.05和编码这种多肽的多核苷酸
CN1331158A (zh) 一种新的多肽——人嘌呤受体9.46和编码这种多肽的多核苷酸
CN1347913A (zh) 一种新的多肽——人凝血栓蛋白29.37和编码这种多肽的多核苷酸
CN1352184A (zh) 一种新的多肽——人嘌呤受体9.68和编码这种多肽的多核苷酸
CN1326943A (zh) 一种新的多肽——结合蛋白RanBP236.85和编码这种多肽的多核苷酸
CN1331100A (zh) 一种新的多肽——结合蛋白RanBP15.29和编码这种多肽的多核苷酸
CN1345972A (zh) 一种新的多肽——枯草蛋白酶14.08和编码这种多肽的多核苷酸
CN1326944A (zh) 一种新的多肽——Symplekin8.91和编码这种多肽的多核苷酸
CN1326960A (zh) 一种新的多肽——糖基磷脂酰肌醇聚糖f10.89和编码这种多肽的多核苷酸
CN1364878A (zh) 一种新的多肽——人染色体精氨酸转运atp酶45.98和编码这种多肽的多核苷酸
CN1382710A (zh) 一种多肽——人转运蛋白－53.24和编码这种多肽的多核苷酸
CN1344731A (zh) 一种新的多肽——人兴奋型氨基酸转运器12.65和编码这种多肽的多核苷酸
CN1328030A (zh) 一种新的多肽——人抑癌基因98和编码这种多肽的多核苷酸
CN1351021A (zh) 一种新的多肽——结合蛋白RanBP10.23和编码这种多肽的多核苷酸
CN1328138A (zh) 一种新的多肽——人rna环化酶12和编码这种多肽的多核苷酸
CN1300774A (zh) 一种新的多肽－人凝血栓蛋白46和编码这种多肽的多核苷酸
CN1510042A (zh) 一种多肽——人pax蛋白12和编码这种多肽的多核苷酸
CN1311210A (zh) 一种新的多肽——人锌指蛋白49和编码这种多肽的多核苷酸
CN1341646A (zh) 一种新的多肽——人大蛋白52.69和编码这种多肽的多核苷酸

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C53 Correction of patent of invention or patent application
COR Change of bibliographic data

Free format text: CORRECT: PATENTEE; FROM: CYTOMED, INC. TO: QIANNIAN MEDICINE CORP.

CP01 Change in the name or title of a patent holder

Patentee after: Thousand Years Medicaments Inc

Patentee before: Cytomed Inc.

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee